DDInter927 DDInter666
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
Eribulin {u} (Compound) treats {v} (Disease) breast cancer
Eribulin {u} (Compound) binds {v} (Gene) TUBB
Eribulin {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Eribulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Verapamil
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paliperidone
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Eribulin {u} may lead to a major life threatening interaction when taken with {v} Escitalopram
Eribulin (Compound) treats breast cancer (Disease)
Eribulin (Compound) binds TUBB (Gene)
Eribulin (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Eribulin may cause a minor interaction that can limit clinical effects when taken with Verapamil
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Eribulin may lead to a major life threatening interaction when taken with Escitalopram